Top

14-08-2018 | ANCA-associated vasculitis | Review | Article

B cell therapy in ANCA-associated vasculitis: current and emerging treatment options

Journal: Nature Reviews Rheumatology

Authors: Mark McClure, Seerapani Gopaluni, David Jayne, Rachel Jones

Publisher: Nature Publishing Group UK

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an organ-threatening and life-threatening multi-system autoimmune disease in which B cell-derived ANCAs cause neutrophil activation and endothelial damage, strongly implicating these autoantibodies in the pathogenesis of AAV. B cell depletion with rituximab combined with glucocorticoids is associated with a reduction in ANCA concentrations and with clinical remission in the majority of patients with AAV. However, the safety profile of rituximab is no better than that of conventional therapy with cyclophosphamide, and long-term glucocorticoid treatment is needed to achieve and maintain disease-free remission. A need for new therapies exists to reduce the time to remission, to spare the use of glucocorticoids and to promote long-lasting remission without the risk of relapse. Over the past 20 years, there has been great interest in therapeutically targeting B cell cytokines, such as B cell-activating factor (BAFF), in many autoimmune disease settings. Dual B cell-targeted immunotherapy that combines B cell depletion and BAFF blockade could potentially be more efficacious than targeting either mechanism alone. In this Review, the theoretical background for use of this combination approach in AAV is presented and discussed.

Jennette, J. C. et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 65, 1–11 (2013).

Christiaan Hagen, E. et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis for the EC/BCR project for ANCA assay standardisation. Kidney Int. 53, 743–753 (1998).

Sablé-Fourtassou, R. et al. Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann. Intern. Med. 143, 632–638 (2005).PubMed

Jennette, J. C. & Falk, R. J. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat. Rev. Rheumatol. 10, 463–473 (2014).PubMed

Voswinkel, J. et al. Single cell analysis of B lymphocytes from Wegener’s granulomatosis: B cell receptors display affinity maturation within the granulomatous lesions. Clin. Exp. Immunol. 154, 339–345 (2008).PubMedPubMedCentral

Popa, E. R., Stegeman, C. A., Bos, N. A., Kallenberg, C. G. & Tervaert, J. W. Differential B- and T-cell activation in Wegener’s granulomatosis. J. Allergy Clin. Immunol. 103, 885–894 (1999).PubMed

Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).PubMedPubMedCentral

Hoffman, W., Lakkis, F. G. & Chalasani, G. B cells, antibodies, and more. Clin. J. Am. Soc. Nephrol. 11, 137–154 (2016).PubMed

Brouwer, E. et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener’s granulomatosis and clinically related disorders. Clin. Exp. Immunol. 83, 379–386 (1991).PubMedPubMedCentral

10.

Abdulahad, W. H., van der Geld, Y. M., Stegeman, C. A. & Kallenberg, C. G. M. Persistent expansion of CD4⁺ effector memory T cells in Wegener’s granulomatosis. Kidney Int. 70, 938–947 (2006).PubMed

11.

Morgan, M. D. et al. Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T regulatory cells. Immunology 130, 64–73 (2010).PubMedPubMedCentral

12.

Abdulahad, W. H. et al. Functional defect of circulating regulatory CD4⁺ T cells in patients with Wegener’s granulomatosis in remission. Arthritis Rheum. 56, 2080–2091 (2007).PubMed

13.

Nogueira, E. et al. Serum IL-17 and IL-23 levels and autoantigen-specific T_H17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 25, 2209–2217 (2010).PubMed

14.

McKinney, E. F. et al. A CD8⁺ T cell transcription signature predicts prognosis in autoimmune disease. Nat. Med. 16, 586–591 (2010).PubMedPubMedCentral

15.

Yates, M. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 75, 1583–1594 (2016).PubMed

16.

Chen, M., Yu, F., Zhang, Y. & Zhao, M. H. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine 87, 203–209 (2008).PubMed

17.

Katsumata, Y., Kawaguchi, Y. & Yamanaka, H. Interstitial lung disease with ANCA-associated vasculitis. Clin. Med. Insights Circ. Respir. Pulm. Med. 9, 51–56 (2015).PubMedPubMedCentral

18.

Schönermarck, U., Gross, W. L. & de Groot, K. Treatment of ANCA-associated vasculitis. Nat. Rev. Nephrol. 10, 25–36 (2013).PubMed

19.

de Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461–2469 (2005).PubMed

20.

Faurschou, M. et al. Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3472–3477 (2012).PubMed

21.

Jayne, D. R. W. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18, 2180–2188 (2007).PubMed

22.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00987389 (2018).

23.

Pagnoux, C. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359, 2790–2803 (2008).PubMed

24.

Metzler, C. et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology 46, 1087–1091 (2007).PubMed

25.

Hiemstra, T. F. et al. Mycophenolate mofetil versus azathioprine for remission maintenance in antineutrophil cytoplasmic antibody–associated vasculitis. JAMA 304, 2381 (2010).PubMed

26.

Phillip, R. & Luqmani, R. Mortality in systemic vasculitis: a systematic review. Clin. Exp. Rheumatol. 26, S94–S104 (2008).PubMed

27.

Tan, J. A. et al. Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann. Rheum. Dis. 76, 1566–1574 (2017).PubMed

28.

Morgan, M. D. et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody–associated vasculitides a matched-pair cohort study. Arthritis Rheum. 60, 3493–3500 (2009).PubMed

29.

Lionaki, S. et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 76, 644–651 (2009).PubMedPubMedCentral

30.

Sinico, R. A., Di Toma, L. & Radice, A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun. Rev. 12, 477–482 (2013).PubMed

31.

Bomback, A. S. et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 79, 757–764 (2011).PubMed

32.

Weiner, M. et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol. 10, 1128–1135 (2015).PubMedPubMedCentral

33.

Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417–427 (2013).PubMedPubMedCentral

34.

Holle, J. U. et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann. Rheum. Dis. 71, 327–333 (2012).PubMed

35.

Stevenson, H. C. & Fauci, A. S. Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B cell activation. Immunology 39, 391–397 (1980).PubMedPubMedCentral

36.

Xiao, H. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955–963 (2002).PubMedPubMedCentral

37.

Specks, U., Fervenza, F. C., McDonald, T. J. & Hogan, M. C. Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 44, 2836–2840 (2001).PubMed

38.

Stasi, R. et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 45, 1432–1436 (2006).PubMed

39.

Keogh, K. A., Wylam, M. E., Stone, J. H. & Specks, U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 262–268 (2005).PubMed

40.

Keogh, K. A. et al. Rituximab for refractory Wegener’s granulomatosis. Am. J. Respir. Crit. Care Med. 173, 180–187 (2006).PubMed

41.

Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2 year results of a randomised trial. Ann. Rheum. Dis. 74, 1178–1182 (2015).PubMed

42.

Walsh, M. et al. Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum. 64, 542–548 (2012).PubMed

43.

Smith, R. M. et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3760–3769 (2012).PubMed

44.

Jones, R. B. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60, 2156–2168 (2009).PubMed

45.

Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011–1016 (2008).PubMed

46.

Bunch, D. O. et al. Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. Clin. J. Am. Soc. Nephrol. 8, 382–391 (2013).PubMedPubMedCentral

47.

Guillevin, L. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 371, 1771–1780 (2014).PubMed

48.

Terrier, B. et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2017-212768 (2018).PubMed

49.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01697267 (2018).

50.

Charles, P. et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2017-212878 (2018).

51.

Alberici, F. et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology 54, 1153–1160 (2015).PubMed

52.

Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 64, 3043–3051 (2012).PubMed

53.

Wang, Y. H. et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B cell lymphoma treated with rituximab-containing chemotherapy. Support. Care Cancer 21, 1265–1271 (2013).PubMed

54.

Sagnelli, E., Pisaturo, M., Sagnelli, C. & Coppola, N. Rituximab-based treatment, HCV replication, and hepatic flares. Clin. Dev. Immunol. 2012, 1–5 (2012).

55.

Roberts, D. M. et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J. Autoimmun. 57, 60–65 (2015).PubMed

56.

Roberts, D. M. et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J. Autoimmun. 57, 24–29 (2015).PubMed

57.

Venhoff, N. et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE 7, e37626 (2012).PubMedPubMedCentral

58.

Kaplan, B., Kopyltsova, Y., Khokhar, A., Lam, F. & Bonagura, V. Rituximab and immune deficiency: case series and review of the literature. J. Allergy Clin. Immunol. Pract. 2, 594–600 (2014).PubMed

59.

Warnatz, K. et al. B cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc. Natl Acad. Sci. USA 106, 13945–13950 (2009).PubMed

60.

Kapetanovic, M. C. et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res. Ther. 16, R2 (2014).PubMedPubMedCentral

61.

Bingham, C. O. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 62, 64–74 (2010).PubMed

62.

Czuczman, M. S. et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 119, 3698–3704 (2012).PubMed

63.

Østergaard, M. et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 62, 2227–2238 (2010).PubMed

64.

McAdoo, S. P. et al. Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. Rheumatology 55, 1437–1442 (2016).PubMed

65.

McAdoo, S. P. et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol. Dial. Transplant. 33, 899 (2018).PubMed

66.

Bologna, L. et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J. Immunol. 186, 3762–3769 (2011).PubMed

67.

Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101–1110 (2014).PubMed

68.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02550652 (2018).

69.

Ruderman, E. M. & Pope, R. M. The evolving clinical profile of abatacept (CTLA4 Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 7, S21–S25 (2005).PubMedPubMedCentral

70.

Langford, C. A. et al. An open-label trial of abatacept (CTLA4 Ig) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann. Rheum. Dis. 73, 1376–1379 (2014).PubMed

71.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02108860 (2017).

72.

Walsh, M., Chaudhry, A. & Jayne, D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH 1H). Ann. Rheum. Dis. 67, 1322–1327 (2007).PubMed

73.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01405807 (2011).

74.

Mackay, F., Schneider, P., Rennert, P. & Browning, J. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231–264 (2003).PubMed

75.

Rauch, M., Tussiwand, R., Bosco, N. & Rolink, A. G. Crucial role for BAFF-BAFF R signaling in the survival and maintenance of mature B cells. PLoS ONE 4, e5456 (2009).PubMedPubMedCentral

76.

Schiemann, B. et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293, 2111–2114 (2001).PubMed

77.

Sasaki, Y., Casola, S., Kutok, J. L., Rajewsky, K. & Schmidt-Supprian, M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J. Immunol. 173, 2245–2252 (2004).PubMed

78.

Shulga-Morskaya, S. et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol. 173, 2331–2341 (2004).PubMed

79.

Stadanlick, J. E. et al. Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling. Nat. Immunol. 9, 1379–1387 (2008).PubMedPubMedCentral

80.

O’Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91–98 (2004).PubMedPubMedCentral

81.

Xu, S. & Lam, K. P. B cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell. Biol. 21, 4067–4074 (2001).PubMedPubMedCentral

82.

Yan, M. et al. Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2, 638–643 (2001).PubMed

83.

Salzer, U. et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat. Genet. 37, 820–828 (2005).PubMed

84.

Salzer, U., Jennings, S. & Grimbacher, B. To switch or not to switch — the opposing roles of TACI in terminal B cell differentiation. Eur. J. Immunol. 37, 17–20 (2007).PubMed

85.

Thien, M. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785–798 (2004).PubMed

86.

Lesley, R. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441–453 (2004).PubMed

87.

Liu, Z. & Davidson, A. BAFF and selection of autoreactive B cells. Trends Immunol. 32, 388–394 (2011).PubMedPubMedCentral

88.

Schneeweis, C. et al. Increased levels of BLyS and sVCAM 1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin. Exp. Rheumatol. 28 (Suppl. 57), 62–66 (2010).PubMed

89.

Xin, G. et al. Serum B cell activating factor in myecloperoxiase-antineutrophil cytoplasmic antibodies-associated vasculitis. Am. J. Med. Sci. 348, 25–29 (2014).PubMed

90.

Nagai, M. et al. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron. Clin. Pract. 118, c339–c345 (2011).PubMed

91.

Sanders, J. S. F., Huitma, M. G., Kallenberg, C. G. M. & Stegeman, C. A. Plasma levels of soluble interleukin 2 receptor, soluble CD30, IL-10 and BAFF during follow-up in vasculitis associated with proteinase 3 antineutrophil cytoplasmic antibodies: associations with disease activity and relapse. Ann. Rheum. Dis. 65, 1484–1489 (2006).PubMedPubMedCentral

92.

Bader, L., Koldingsnes, W. & Nossent, J. B lymphocyte activating factor levels are increased in patients with Wegener’s granulomatosis and inversely correlated with ANCA titer. Clin. Rheumatol. 29, 1031–1035 (2010).PubMed

93.

De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137–148 (2015).PubMedPubMedCentral

94.

Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160–171 (2015).PubMed

95.

Vinuesa, C. G., Sanz, I. & Cook, M. C. Dysregulation of germinal centres in autoimmune disease. Nat. Rev. Immunol. 9, 845–857 (2009).PubMed

96.

Balázs, M., Martin, F., Zhou, T. & Kearney, J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T independent immune responses. Immunity 17, 341–352 (2002).PubMed

97.

Rahman, Z. S., Rao, S. P., Kalled, S. L. & Manser, T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF R signaling–deficient mice. J. Exp. Med. 198, 1157–1169 (2003).PubMedPubMedCentral

98.

Gatto, D. & Brink, R. The germinal center reaction. J. Allergy Clin. Immunol. 126, 898–907 (2010).PubMed

99.

Kalled, S. L. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 18, 290–296 (2006).PubMed

100.

Goenka, R. et al. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J. Exp. Med. 211, 45–56 (2014).PubMedPubMedCentral

101.

Coquery, C. M. et al. BAFF regulates follicular helper T cells and affects their accumulation and interferon γ production in autoimmunity. Arthritis Rheumatol. 67, 773–784 (2015).PubMedPubMedCentral

102.

Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447–462 (2014).PubMed

103.

Mueller, A., Holl-Ulrich, K., Lamprecht, P. & Gross, W. L. Germinal centre-like structures in Wegener’s granuloma: the morphological basis for autoimmunity? Rheumatology 47, 1111–1113 (2008).PubMed

104.

Voswinkel, J., Muller, A. & Lamprecht, P. Is PR3 ANCA formation initiated in Wegener’s granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann. NY Acad. Sci. 1051, 12–19 (2005).PubMed

105.

Zhao, Y. et al. Granulomatosis with polyangiitis involves sustained mucosal inflammation that is rich in B cell survival factors and autoantigen. Rheumatology 51, 1580–1586 (2012).PubMed

106.

Parsa, R. et al. BAFF-secreting neutrophils drive plasma cell responses during emergency granulopoiesis. J. Exp. Med. 213, 1537–1553 (2016).PubMedPubMedCentral

107.

Holden, N. J. et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann. Rheum. Dis. 70, 2229–2233 (2011).PubMed

108.

Bertram, A. et al. Circulating ADAM17 level reflects disease activity in proteinase 3 ANCA-associated vasculitis. J. Am. Soc. Nephrol. 26, 2860–2870 (2015).PubMedPubMedCentral

109.

Smulski, C. R. et al. BAFF- and TACI-dependent processing of BAFFR by ADAM proteases regulates the survival of B cells. Cell Rep. 18, 2189–2202 (2017).PubMed

110.

Kreuzaler, M. et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J. Immunol. 188, 497–503 (2012).PubMed

111.

Carter, L. M., Isenberg, D. A. & Ehrenstein, M. R. Elevated serum BAFF levels are associated with rising anti–double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 65, 2672–2679 (2013).PubMed

112.

Silverman, G. J. Therapeutic B cell depletion and regeneration in rheumatoid arthritis emerging patterns and paradigms. Arthritis Rheum. 54, 2356–2367 (2006).PubMed

113.

Baker, K. P. et al. Generation and characterization of LymphoStat B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253–3265 (2003).PubMed

114.

Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).PubMed

115.

Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).PubMedPubMedCentral

116.

Ginzler, E. M. et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J. Rheumatol. 41, 300–309 (2014).PubMed

117.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01639339 (2018).

118.

Stohl, W. et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64, 2328–2337 (2012).PubMedPubMedCentral

119.

Halpern, W. G. et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol. Sci. 91, 586–599 (2006).PubMed

120.

Lech, M. & Anders, H. J. The pathogenesis of lupus nephritis. J. Am. Soc. Nephrol. 24, 1357–1366 (2013).PubMedPubMedCentral

121.

Thiel, J. et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res. Ther. 19, 101 (2017).PubMedPubMedCentral

122.

Jayne, D. et al. Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: a multicenter randomized, placebo-controlled study [abstract]. Arthritis Rheumatol. 69 (Suppl. 10), 207AD (2017).

123.

Merrill, J. T. et al. Phase III trial results with blisibimod, a selective inhibitor of B cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 77, 883–889 (2018).PubMed

124.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02514967 (2017).

125.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01598857 (2015).

126.

Isenberg, D. A. et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE 1, a 52 week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 323–331 (2016).PubMed

127.

Schiff, M. et al. Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. RMD Open 1, e000037 (2015).PubMedPubMedCentral

128.

Vincent, F. B., Saulep-Easton, D., Figgett, W. A., Fairfax, K. A. & Mackay, F. The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24, 203–215 (2013).PubMed

129.

Ginzler, E. M. et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther. 14, R33 (2012).PubMedPubMedCentral

130.

Merrill, J. T. et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus. Arthritis Rheumatol. 70, 266–276 (2018).PubMedPubMedCentral

131.

Gong, Q. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817–826 (2005).PubMed

132.

Bekar, K. W. et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 62, 2443–2457 (2010).PubMedPubMedCentral

133.

Lin, W. et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheumatol. 67, 215–224 (2015).PubMed

134.

Kraaij, T. et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J. Autoimmun. 91, 45–54 (2018).PubMed

135.

Aranow, C. et al. Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis [abstract]. Ann. Rheum. Dis. 77, A690 (2018).

136.

BEAT Lupus. BEAT Lupus. BEAT Lupus https://beatlupus.uk/ (2017).

137.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03312907 (2018).

138.

US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02631538 (2018).

Medicine Matters Rheumatology

Abstract